{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:06:12Z","timestamp":1789549572015,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.maturitas.2023.04.004","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:29:46Z","timestamp":1681367386000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Oral estradiol\/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens\/medroxyprogesterone acetate in real-world practice"],"prefix":"10.1016","volume":"172","author":[{"given":"Nick","family":"Panay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella E.","family":"Nappi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Paszkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"H\u00e9roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Boolell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2023.04.004_bb0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.maturitas.2021.12.001","article-title":"The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement","volume":"158","author":"Rees","year":"2022","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0010","series-title":"Menopause Practice: A Clinician's Guide","first-page":"43","article-title":"Vasomotor symptoms","author":"Thurston","year":"2019"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2005.09.031","article-title":"Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives","volume":"118","author":"Woods","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0020","series-title":"Health care-seeking for menopausal problems","first-page":"112","volume":"6","author":"Guthrie","year":"2009"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/01.AOG.0000441353.20693.78","article-title":"ACOG Practice Bulletin No. 141: management of menopausal","volume":"123","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0030","first-page":"338","article-title":"Practice guidelines: ACOG releases clinical guidelines on management of menopausal symptoms","volume":"90","author":"Hauk","year":"2014","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fendo.2021.564781","article-title":"Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts","volume":"12","author":"Mehta","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0040","first-page":"321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","year":"2002","journal-title":"JAMA-Express"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0045","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Banks","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0050","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1210\/jc.2012-4070","article-title":"Where are we 10 years after the Women's Health Initiative?","volume":"98","author":"Lobo","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0055","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/GME.0000000000001282","article-title":"Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative study results","volume":"26","author":"Crawford","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/AOG.0000000000002645","article-title":"A 17\u03b2-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial","volume":"132","author":"Lobo","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0065","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/GME.0000000000001306","article-title":"Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)","volume":"26","author":"Lobo","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0070","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/13697137.2018.1455657","article-title":"Evidence on the use of progesterone in menopausal hormone therapy","volume":"21","author":"Mirkin","year":"2018","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0080","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0090","series-title":"SAS GlobForum","first-page":"6","article-title":"A unified approach to measuring the effect size between two groups using SAS\u00ae","author":"Yang","year":"2012"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/13697137.2021.2022644","article-title":"The impact of micronized progesterone on cardiovascular events\u2013a systematic review","author":"Kaemmle","year":"2022","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0120","first-page":"1","article-title":"Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins","author":"Graham","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0125","series-title":"Hormone therapy and venous thromboembolism among postmenopausal women impact of the route of estrogen administration and progestogens: the ESTHER study","author":"Canonico","year":"2007"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0130","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/gme.0b013e3181f9f7c3","article-title":"Hormone therapy and recurrence of venous thromboembolism among postmenopausal women","volume":"18","author":"Oli\u00e9","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0140","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0145","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0150","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/09513590600717368","article-title":"The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits \u2013 an attempt to interpret the Women's Health Initiative results","volume":"22","author":"Kuhl","year":"2009","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bpobgyn.2020.06.002","article-title":"The pharmacodynamics and safety of progesterone","volume":"69","author":"Piette","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.maturitas.2023.04.004_bb0160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"The Women's Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0165","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2023.04.004_bb0180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J. Clin. Epidemiol."}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851222300066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037851222300066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:21:22Z","timestamp":1759915282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037851222300066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"alternative-id":["S037851222300066X"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.04.004","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral estradiol\/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens\/medroxyprogesterone acetate in real-world practice","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2023.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}